The results demonstrated that GBM patients with high expression of Notch3 indicated a shorter survival period, which was similar to the previous reports (Shen et al., 2015) that Notch3 gene polymorphism is associated with the prognosis of gliomas. The gene discussed is NOTCH3; the disease is central nervous system cancer.